Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2011	Dec. 31, 2010
Successor
Current assets:
Cash and cash equivalents	$ 2,606,381	$ 867,738
Accounts receivable, net	238,546	229,891
Inventory, net	266,692	258,939
Prepaid expenses and other current assets	357,575	559,082
Total current assets	3,469,194	1,915,650
Property and equipment, net of accumulated depreciation of $20,675 and $ 8,085, respectively	709,512	21,589
Other assets	250	250
Intangible assets	6,340,656	6,340,656
Total assets	10,519,612	8,278,145
Current liabilities:
Current debt	7,856,206	56,911
Accounts payable	770,211	1,096,125
Accrued expenses	622,738	789,482
Derivative liability-current	1,134,042
Total current liabilities	10,383,197	1,942,518
Long-term debt	0	7,290,881
Deferred tax liability	2,500,000	2,500,000
Warrant liability	18,631,283	8,171,518
Derivative liability	5,468,898	2,120,360
Other long-term liabilities	198,804	255,606
Total liabilities	37,182,182	22,280,883
Commitments and contingencies
Preferred stock		0
Preferred stock series B, $0.001 par value; subscription receivable		210,000
Fibrocell Science, Inc. shareholders' deficit:
Common stock, $0.001 par value; 250,000,000 shares authorized 45,498,230 and 20,375,500 shares issued and outstanding, respectively	45,498	20,376
Additional paid-in capital	17,596,984	2,437,893
Accumulated deficit during development stage	(45,191,992)	(17,981,530)
Total Fibrocell Science, Inc. shareholders' deficit	(27,549,510)	(15,523,261)
Noncontrolling interest	496,925	450,373
Total deficit and noncontrolling interest	(27,052,585)	(15,072,888)
Total liabilities, preferred stock, shareholders' deficit and noncontrolling interest	10,519,612	8,278,145
Successor | Series A Preferred Stock
Current liabilities:
Preferred stock	390,015	1,280,150
Successor | Series B Preferred Stock
Current liabilities:
Preferred stock	0
Preferred stock series B, $0.001 par value; subscription receivable	0
Series D Preferred Stock
Current liabilities:
Preferred stock	$ 0	$ 0